4D Pharma (LON:DDDD) Trading Up 5%
4D Pharma (LON:DDDD) Trading Up 5%
4D pharma plc (LON:DDDD – Get Rating)'s share price was up 5% during trading on Tuesday . The stock traded as high as GBX 16.86 ($0.20) and last traded at GBX 16.66 ($0.20). Approximately 912,370 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 2,957,490 shares. The stock had previously closed at GBX 15.86 ($0.19).
4D pharma plc（LON: DDDD — 获取评级）的股价在周二的交易中上涨了5％。该股的交易价格高达GBX 16.86（0.20美元），最后一次交易价格为GBX 16.66（0.20美元）。午盘交易中交易了约912,370股，较平均每日交易量2,957,490股下降了69％。该股此前收于GBX 15.86（0.19美元）。
4D pharma Stock Up 5.0 %
4D 制药股价上涨5.0％
The company has a quick ratio of 4.72, a current ratio of 5.21 and a debt-to-equity ratio of 39.50. The company has a fifty day simple moving average of GBX 16.66 and a 200 day simple moving average of GBX 28.63. The firm has a market capitalization of £30.04 million and a P/E ratio of -1.08.
该公司的速动比率为4.72，流动比率为5.21，债务与权益比率为39.50。该公司的五十天简单移动平均线为GBX 16.66，200天简单移动平均线为GBX 28.63。该公司的市值为3,04万英镑，市盈率为-1.08。
About 4D pharma
关于 4D 制药
(Get Rating)
（获取评级）
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.
4D pharma plc及其子公司在英国开发活生物治疗产品（LBP）。该公司开发候选治疗药物，包括用于治疗癌症和免疫肿瘤学疾病的mrx0518；用于治疗哮喘的mrx-4dp0004；治疗中枢神经系统疾病的mrx0029和mrx0005；治疗肠易激综合征的Blautix；以及用于小儿克罗恩病的Thetanix。
Further Reading
进一步阅读
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- 这就是现在对标准普尔500指数的期望
- 关于 Oracle 的 FQ1 报告，你需要知道的两件事
- 波动市场的三只价值股票
- 3 只能源股接近从杯形模式中突破
- 这些股息成就者值得在你的投资组合中占有一席之地吗？
Receive News & Ratings for 4D pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日4D制药的新闻和评级 -在下面输入您的电子邮件地址，以通过Marketbeat.com的免费每日电子邮件时事通讯接收4D制药及相关公司最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。